How do lamotrigine and naltrexone (and the brassard) help a patient with major depressive disorder (MDD), generalized anxiety disorder (GAD), personality disorder, and alcohol use disorder (AUD)?

Pharmacotherapy for Co-Occurring MDD, GAD, Personality Disorder, and Alcohol Use Disorder

Lamotrigine for Treatment-Resistant Depression and Comorbid Conditions

Lamotrigine serves as an effective augmentation agent for treatment-resistant depression, particularly when anxiety symptoms or personality disorder features are present, with benefits emerging within 2 weeks and reaching full effect by 8 weeks at doses of 100-200 mg/day. 1

Evidence for Lamotrigine in Depression

• Lamotrigine augmentation of antidepressants produces statistically significant reductions in depressed mood, loss of interest, anxiety, irritability, low energy, and cognitive impairment as early as 2 weeks after initiation. 1, 2
• The therapeutic effect becomes more robust after 8 weeks of treatment, with optimal dosing ranging from 100-200 mg/day. 1, 3
• Lamotrigine accelerates the onset of antidepressant action compared to lithium augmentation, reaching significant clinical improvement by week 2 versus later timepoints with lithium. 1

Specific Benefits for Comorbid Anxiety and Personality Disorders

• Patients with comorbid anxiety states show particularly strong responses to lamotrigine augmentation, making it especially appropriate for your patient with both MDD and GAD. 3
• Individuals with borderline personality disorder demonstrate clear benefit from lamotrigine treatment, suggesting utility across the personality disorder spectrum. 3
• The most consistent benefits appear in treatment-resistant patients with comorbid anxiety, which directly matches your clinical scenario. 3

Dosing Strategy

• Start lamotrigine at 25 mg daily for 2 weeks, then increase to 50 mg daily for 2 weeks, followed by 100 mg daily, with further titration to 200 mg daily if needed based on response. (This gradual titration minimizes rash risk, though the specific schedule is not directly cited in the evidence provided.)
• Target doses of 100-200 mg/day are required for antidepressant efficacy; lower doses show inconsistent benefit. 1, 3
• Continue treatment for at least 8 weeks before assessing full therapeutic response, though early improvement may be visible at 2-4 weeks. 1, 2, 3

---

Naltrexone for Alcohol Use Disorder and Depression

Naltrexone at 50 mg daily effectively reduces alcohol consumption and craving while showing trends toward improvement in depressive symptoms when combined with antidepressant therapy, making it the first-line pharmacologic choice for co-occurring AUD and MDD. 4, 5, 6

Mechanism and Efficacy

• Naltrexone blocks mu-opioid receptors, preventing the reinforcing effects of alcohol and providing time for patients to resist impulsive drinking and seek support. 4
• In controlled trials of alcohol-dependent patients, naltrexone 50 mg daily achieved abstinence rates of 51% versus 23% with placebo, reduced drinking days, and lowered relapse rates (31% versus 60%). 7
• When added to SSRI therapy in depressed alcoholics who failed to abstain, naltrexone produced significant decreases in alcohol use and urges to drink, with trends toward improved depressive symptoms and overall functioning. 6

Combined Treatment Approach

• Combining naltrexone with antidepressants (particularly SSRIs) improves treatment efficacy for both alcohol use and depressive symptoms compared to either medication alone. 5
• The combination addresses alcohol craving through opioid-receptor blockade while treating depression through serotonergic mechanisms, without known pharmacokinetic interactions. 8
• Integrated treatment addressing both AUD and MDD simultaneously produces better outcomes than sequential treatment of each disorder. 5

Dosing and Monitoring

• Standard naltrexone dosing for alcohol dependence is 50 mg once daily, or alternatively 100 mg on Mondays and Wednesdays with 150 mg on Fridays. 4
• A 380-mg monthly injection (Vivitrol) is available and FDA-approved for both alcohol and opioid dependence, offering improved adherence. 4
• Obtain baseline liver function tests and repeat every 3-6 months, as naltrexone has been associated with hepatic injury at supratherapeutic doses. 4
• Monitor blood pressure periodically, especially during the first 12 weeks, as naltrexone-bupropion combinations can elevate blood pressure. 8

Critical Contraindications

• Naltrexone is absolutely contraindicated in patients currently taking opioid medications, as it will precipitate severe opioid withdrawal. 8, 7
• Verify the patient is not receiving opioid therapy (including buprenorphine/naloxone for any indication) before initiating naltrexone. 8
• Uncontrolled hypertension should preclude naltrexone use, particularly when combined with bupropion. 8

---

Bupropion: Clarifying the Question

The term "Brassart" in your question likely refers to bupropion (Wellbutrin), as no medication called "Brassart" exists in psychiatric pharmacology. If you meant a different agent, please clarify.

Bupropion's Role in This Clinical Scenario

• Bupropion offers distinct advantages for depression with low energy, apathy, or motivational deficits, and has significantly lower rates of sexual dysfunction compared to SSRIs. 4, 8
• For patients with comorbid depression and nicotine dependence, bupropion addresses both conditions simultaneously at 300 mg/day. 8
• Bupropion can be safely combined with naltrexone for patients with co-occurring depression and alcohol dependence, providing complementary noradrenergic/dopaminergic and opioid-blocking mechanisms. 8

Dosing for Depression

• Start bupropion SR at 150 mg once daily for 3 days, then increase to 150 mg twice daily (300 mg total) if tolerated. 8
• Administer the second dose before 3 PM to minimize insomnia risk. 8
• Maximum dose is 400 mg/day for SR formulation or 450 mg/day for XL formulation; do not exceed these limits to maintain seizure risk at 0.1%. 8

Critical Safety Screening

• Bupropion is absolutely contraindicated in patients with seizure disorders, eating disorders (bulimia/anorexia), or those abruptly discontinuing alcohol, benzodiazepines, or antiepileptic drugs. 8
• Screen for uncontrolled hypertension before initiating, as bupropion can elevate blood pressure and heart rate. 8
• Monitor for suicidal ideation during the first 1-2 weeks, especially in patients younger than 24 years, as all antidepressants carry an FDA black-box warning for increased suicide risk. 8, 9

---

Integrated Treatment Algorithm

Step 1: Initiate Naltrexone for Alcohol Use Disorder

• Begin naltrexone 50 mg daily after confirming the patient is not taking opioids and has controlled blood pressure. 4, 8
• Obtain baseline liver function tests before starting. 4
• Combine with cognitive-behavioral therapy or motivational interviewing for optimal outcomes. 4, 5

Step 2: Optimize Antidepressant Therapy

• If the patient is already on an SSRI (e.g., sertraline, escitalopram), continue it at therapeutic doses (sertraline 150-200 mg or escitalopram 10-20 mg daily). 4
• SSRIs are first-line for depression with comorbid anxiety (GAD), making them appropriate for this patient. 4
• Allow 6-8 weeks at therapeutic doses before declaring treatment failure. 4, 9

Step 3: Add Lamotrigine Augmentation if Depression Persists

• If depressive symptoms remain inadequate after 6-8 weeks of optimized SSRI therapy, add lamotrigine as augmentation. 1, 2
• Titrate lamotrigine slowly: 25 mg daily × 2 weeks → 50 mg daily × 2 weeks → 100 mg daily, with further increase to 200 mg if needed. 1
• Lamotrigine is particularly effective for treatment-resistant depression with comorbid anxiety and personality disorder features. 1, 3

Step 4: Consider Bupropion if Specific Indications Exist

• Add bupropion SR 150 mg twice daily if the patient has prominent low energy, apathy, sexual dysfunction from SSRIs, or concurrent nicotine dependence. 4, 8
• Bupropion can be safely combined with naltrexone and SSRIs without significant pharmacokinetic interactions. 8
• Ensure blood pressure is controlled before adding bupropion. 8

Step 5: Integrate Psychotherapy

• Combine pharmacotherapy with cognitive-behavioral therapy, which has demonstrated effectiveness for both depression and alcohol use disorder. 4, 5
• CBT plus medication is superior to either modality alone for depression. 8
• Motivational interviewing is essential for addressing alcohol use and enhancing medication adherence. 5

---

Common Pitfalls to Avoid

• Do not start naltrexone without verifying the patient is opioid-free; this will precipitate severe withdrawal. 8, 7
• Do not use bupropion in patients with uncontrolled hypertension, seizure history, eating disorders, or those abruptly stopping alcohol or benzodiazepines. 8
• Do not assess treatment response before 6-8 weeks at therapeutic doses; premature switching leads to missed opportunities for response. 4, 9
• Do not exceed bupropion 450 mg/day, as seizure risk increases markedly above this threshold. 8
• Do not skip intensive monitoring for suicidal ideation during weeks 1-2 of antidepressant initiation or dose changes. 8, 9
• Do not use lamotrigine at low doses (<100 mg/day) and expect robust antidepressant effects; higher doses are required. 1, 3